The STARSCAPE trial, a phase III, double-blind, placebo-controlled study, evaluated the efficacy and safety of zinpentraxin alfa in patients with idiopathic pulmonary fibrosis (IPF). The trial enrolled 664 patients randomized 1:1 to receive either placebo or zinpentraxin alfa 10 mg/kg every 4 weeks. The primary endpoint was the absolute change in forced vital capacity (FVC) from baseline to Week 52, with no statistically significant difference observed between treatment groups (-214.89 ml vs. -235.72 ml; P=0.5420). Secondary endpoints, including percent predicted FVC and 6-minute walk distance (6MWD), also showed no significant treatment effects. The trial was terminated early after a prespecified futility analysis, which showed no benefit of zinpentraxin alfa over placebo. Post hoc analysis of phase II and III data revealed that extreme FVC declines in two placebo-treated patients influenced the phase II results, suggesting that outliers can impact trial outcomes. Despite this, the phase III trial did not show any clinical benefit of zinpentraxin alfa over placebo. Safety data showed that 72.3% of placebo-treated patients and 74.6% of zinpentraxin alfa-treated patients experienced at least one adverse event, with common events including COVID-19, cough, and diarrhea. No significant differences in serious adverse events were observed between groups. The study highlights the importance of analyzing data at the patient level to identify and address outliers, which can significantly affect trial outcomes. The results emphasize the need for careful data interpretation in IPF trials, particularly when using FVC as an endpoint. The trial also underscores the challenges of interpreting results from small phase II trials and the importance of considering alternative endpoints in future studies. Overall, zinpentraxin alfa did not demonstrate clinical benefit over placebo in patients with IPF.The STARSCAPE trial, a phase III, double-blind, placebo-controlled study, evaluated the efficacy and safety of zinpentraxin alfa in patients with idiopathic pulmonary fibrosis (IPF). The trial enrolled 664 patients randomized 1:1 to receive either placebo or zinpentraxin alfa 10 mg/kg every 4 weeks. The primary endpoint was the absolute change in forced vital capacity (FVC) from baseline to Week 52, with no statistically significant difference observed between treatment groups (-214.89 ml vs. -235.72 ml; P=0.5420). Secondary endpoints, including percent predicted FVC and 6-minute walk distance (6MWD), also showed no significant treatment effects. The trial was terminated early after a prespecified futility analysis, which showed no benefit of zinpentraxin alfa over placebo. Post hoc analysis of phase II and III data revealed that extreme FVC declines in two placebo-treated patients influenced the phase II results, suggesting that outliers can impact trial outcomes. Despite this, the phase III trial did not show any clinical benefit of zinpentraxin alfa over placebo. Safety data showed that 72.3% of placebo-treated patients and 74.6% of zinpentraxin alfa-treated patients experienced at least one adverse event, with common events including COVID-19, cough, and diarrhea. No significant differences in serious adverse events were observed between groups. The study highlights the importance of analyzing data at the patient level to identify and address outliers, which can significantly affect trial outcomes. The results emphasize the need for careful data interpretation in IPF trials, particularly when using FVC as an endpoint. The trial also underscores the challenges of interpreting results from small phase II trials and the importance of considering alternative endpoints in future studies. Overall, zinpentraxin alfa did not demonstrate clinical benefit over placebo in patients with IPF.